Home › Companies › SPYRE THERAPEUTICS INC. › 2023-2024
At SPYRE THERAPEUTICS INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held November 21, 2023 and May 13, 2024), 78 asset managers reported how they voted in their SEC Form N-PX filings, covering 531 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held May 13, 2024 — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — SPYRE THERAPEUTICS INC.'s filing reports the proposal as approved, with 62% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SPYRE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SPYRE THERAPEUTICS INC.’s Form 8-K, filed May 15, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 13, 2024: 7 items on SPYRE THERAPEUTICS INC.’s Form 8-K, filed May 15, 2024: 5 approved · 2 without a stated outcome.
Meeting of November 21, 2023: 4 items on SPYRE THERAPEUTICS INC.’s Form 8-K, filed November 24, 2023: 4 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore SPYRE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are SPYRE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. SPYRE THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey W. Albers | 22,252,788 | -- | -- | 5,909,047 | 945,466 | 79% | Not verified | — |
| Elect Director: Tomas Kiselak | 22,016,240 | -- | -- | 6,145,595 | 945,466 | 78% | Not verified | — |
| 2. On a non-binding, advisory basis, the compensation of the Company's named executive officers | 17,465,368 | 10,689,515 | 6,952 | -- | 945,466 | 62% | Approved | — |
| 3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 | 29,096,079 | 10,509 | 713 | -- | 0 | 99.9% | Approved | — |
| 4. The issuance of Common Stock upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), issued in December 2023 | 28,136,379 | 18,517 | 6,939 | -- | 945,466 | 99.9% | Approved | — |
| 5. An amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation | 26,588,617 | 1,572,985 | 233 | -- | 945,466 | 94% | Approved | — |
| 6. An adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies | 19,695,462 | 8,458,691 | 7,682 | -- | 945,466 | 70% | Approved | — |
Source: SPYRE THERAPEUTICS INC., Form 8-K, filed with the SEC on May 15, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. For the purpose of complying with the applicable provisions of Nasdaq Listing Rule 5635(a), the issuance of up to 43,453,560 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), upon conversion of the Company's Series A Non-Vo | 2,457,804 | 17,677 | 529 | -- | 507,572 | 99.2% | Approved | — |
| 2. The amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan | 2,244,907 | 748,367 | 545 | -- | 507,572 | 75% | Approved | — |
| 3. And approved an amendment to the Company's Certificate of Incorporation, as amended and restated, to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000 | 3,237,929 | 261,504 | 1,958 | -- | -- | 93% | Approved | — |
| 4. And approved an adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals 1, 2 and/or 3 | 2,848,064 | 651,163 | 2,164 | -- | -- | 81% | Approved | — |
Source: SPYRE THERAPEUTICS INC., Form 8-K, filed with the SEC on November 24, 2023 — read the filing on EDGAR.
Each item below shows how the 78 asset managers that disclosed a SPYRE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SPYRE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2027: Jeffrey W. Albers
SPYRE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey W. Albers”): 22,252,788 for, 5,909,047 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 1,036,635 for, 4,292,536 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 146,537 | 0 | 0 | 4,292,536 | Withhold |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 19,896 | 0 | 0 | 0 | For |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 23 | 0 | 0 | 0 | For |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2027: Tomas Kiselak
SPYRE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Tomas Kiselak”): 22,016,240 for, 6,145,595 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 1,036,612 for, 4,292,559 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 146,537 | 0 | 0 | 4,292,536 | Withhold |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 19,896 | 0 | 0 | 0 | For |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 23 | Withhold |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation.
SPYRE THERAPEUTICS INC.’s own tally for this item (“5. An amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation”): 26,588,617 for, 1,572,985 against — passed, per its Form 8-K filed May 15, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4b The Company's stockholders approved the issuance of Common Stock upon conversion of the Company's Series B Preferred Stock issued in March 2024.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 5,054,175 for, 274,996 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,439,073 | 0 | 0 | 0 | For |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 255,100 | 0 | 0 | Against |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 19,896 | 0 | 0 | Against |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 23 | 0 | 0 | 0 | For |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company's common stock upon conversion of the Company's Series B Convertible Preferred Stock issued in December 2023.
SPYRE THERAPEUTICS INC.’s own tally for this item (“4. The issuance of Common Stock upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), issued in December 2023”): 28,136,379 for, 18,517 against — passed, per its Form 8-K filed May 15, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4a The Company's stockholders approved the issuance of Common Stock upon conversion of the Company's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), issued in December 2023.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 5,329,148 for, 23 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,439,073 | 0 | 0 | 0 | For |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 19,896 | 0 | 0 | 0 | For |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 0 | 23 | 0 | 0 | Against |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company's common stock upon conversion of the Company's Series B Convertible Preferred Stock issued in March 2024.
The 14 asset managers below reported 5,294,051 for, 23 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,439,073 | 0 | 0 | 0 | For |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| State Street | 0 | 23 | 0 | 0 | Against |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held November 21, 2023.
93% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Certificate of Incorporation, as amended and restated, to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000 ("Proposal No. 3").
SPYRE THERAPEUTICS INC.’s own tally for this item (“3. And approved an amendment to the Company's Certificate of Incorporation, as amended and restated, to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000”): 3,237,929 for, 261,504 against — passed, per its Form 8-K filed November 24, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 The Company's stockholders adopted and approved an amendment to the Company's Certificate of Incorporation, as amended and restated, to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 25,878 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,349 | 0 | 0 | 0 | For |
| Fidelity | 8,778 | 0 | 0 | 0 | For |
| Legg Mason | 1,202 | 0 | 0 | 0 | For |
| Dimensional | 1,098 | 0 | 0 | 0 | For |
| Victory Capital | 390 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 52 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
70% Approved · of votes cast
Description as filed by funds: To approve an adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies.
SPYRE THERAPEUTICS INC.’s own tally for this item (“6. An adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies”): 19,695,462 for, 8,458,691 against — passed, per its Form 8-K filed May 15, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 6 The Company's stockholders approved an adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 767,418 for, 4,561,753 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,348 | 4,428,725 | 0 | 0 | Against |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 121,296 | 0 | 0 | Against |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 19,896 | 0 | 0 | 0 | For |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 5,300 | 0 | 0 | Against |
| John Hancock | 0 | 4,466 | 0 | 0 | Against |
| CARILLON SERIES TRUST | 0 | 986 | 0 | 0 | Against |
| BNY Mellon | 0 | 504 | 0 | 0 | Against |
| American Century | 0 | 275 | 0 | 0 | Against |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 0 | 150 | 0 | 0 | Against |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 0 | 23 | 0 | 0 | Against |
| Nationwide | 0 | 19 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
Meeting held November 21, 2023.
81% Approved · of votes cast
Description as filed by funds: To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2, and/or 3 ("Proposal No. 4").
SPYRE THERAPEUTICS INC.’s own tally for this item (“4. And approved an adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals 1, 2 and/or 3”): 2,848,064 for, 651,163 against — passed, per its Form 8-K filed November 24, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 The Company's stockholders adopted and approved an adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for ”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 14,349 for, 11,529 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,349 | 0 | 0 | 0 | For |
| Fidelity | 0 | 8,778 | 0 | 0 | Against |
| Legg Mason | 0 | 1,202 | 0 | 0 | Against |
| Dimensional | 0 | 1,098 | 0 | 0 | Against |
| Victory Capital | 0 | 390 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 52 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
Meeting held November 21, 2023.
99.2% Approved · of votes cast
Description as filed by funds: To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Proposal No. 1").
SPYRE THERAPEUTICS INC.’s own tally for this item (“1. For the purpose of complying with the applicable provisions of Nasdaq Listing Rule 5635(a), the issuance of up to 43,453,560 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), upon con”): 2,457,804 for, 17,677 against — passed, per its Form 8-K filed November 24, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The final voting results were as follows: Proposal No. 1 The Company's stockholders approved, for the purpose of complying with the applicable provisions of Nasdaq Listing Rule 5635(a), the issuance of up to 43,453,560 shares of the Company's common stock, par value $0.0001 per share ("Common Stock…”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 25,878 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,349 | 0 | 0 | 0 | For |
| Fidelity | 8,778 | 0 | 0 | 0 | For |
| Legg Mason | 1,202 | 0 | 0 | 0 | For |
| Dimensional | 1,098 | 0 | 0 | 0 | For |
| Victory Capital | 390 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 52 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Meeting held November 21, 2023.
75% Approved · of votes cast
Description as filed by funds: To approve an amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan ("Proposal No. 2").
SPYRE THERAPEUTICS INC.’s own tally for this item (“2. The amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan”): 2,244,907 for, 748,367 against — passed, per its Form 8-K filed November 24, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The Company's stockholders approved the amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 25,878 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 14,349 | 0 | 0 | Against |
| Fidelity | 0 | 8,778 | 0 | 0 | Against |
| Legg Mason | 0 | 1,202 | 0 | 0 | Against |
| Dimensional | 0 | 1,098 | 0 | 0 | Against |
| Victory Capital | 0 | 390 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 52 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
Meeting held May 13, 2024.
Combines 8 wordings of this item as funds reported it.
62% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
SPYRE THERAPEUTICS INC.’s own tally for this item (“2. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 17,465,368 for, 10,689,515 against — passed, per its Form 8-K filed May 15, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 62% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 4,439,073 | 0 | 0 | Against |
| Vanguard | 0 | 430,802 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 255,100 | 0 | 0 | Against |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 0 | 36,071 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 19,896 | 0 | 0 | Against |
| Charles Schwab | 0 | 15,000 | 0 | 0 | Against |
| ETFis Series Trust I | 0 | 5,300 | 0 | 0 | Against |
| John Hancock | 4,400 | 66 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 986 | 0 | 0 | Against |
| BNY Mellon | 0 | 504 | 0 | 0 | Against |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 23 | 0 | 0 | 0 | For |
| Nationwide | 0 | 19 | 0 | 0 | Against |
| Guggenheim | 0 | 9 | 0 | 0 | Against |
Fund voting reports, all 18 managers: 126,345 for, 5,202,826 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 5,895,254 | 0 | 0 | Against |
| VR Adviser, LLC | 2,122,714 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,839,138 | 0 | 0 | 0 | For |
| COMMODORE CAPITAL LP | 1,834,084 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,426,091 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 978,420 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 900,000 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 741,904 | 0 | 0 | Against |
| Cormorant Asset Management, LP | 687,080 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 687,080 | 0 | 0 | Against |
| Wellington | 500,998 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 466,000 | 0 | 0 | Against |
| Citadel | 412,294 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 266,680 | 0 | 0 | Against |
| Affinity Asset Advisors, LLC | 171,708 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 167,167 | 0 | 0 | Against |
| HighVista Strategies LLC | 154,381 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 151,954 | 0 | 0 | 0 | For |
| T. Rowe Price | 146,746 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0 | 132,052 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 117,204 | 0 | 0 | Against |
| Candriam S.C.A. | 0 | 105,000 | 0 | 0 | Against |
| BlackRock | 341 | 89,928 | 0 | 0 | Against |
| Woodline Partners LP | 67,527 | 0 | 0 | 0 | For |
| Point72 | 0 | 65,308 | 0 | 0 | Against |
Institutional-manager reports, all 62 managers: 10,521,170 for, 9,906,628 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held May 13, 2024.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.
SPYRE THERAPEUTICS INC.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 29,096,079 for, 10,509 against — passed, per its Form 8-K filed May 15, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 5,329,171 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,439,073 | 0 | 0 | 0 | For |
| Vanguard | 430,802 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 255,100 | 0 | 0 | 0 | For |
| T. Rowe Price | 121,296 | 0 | 0 | 0 | For |
| BlackRock | 36,071 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 19,896 | 0 | 0 | 0 | For |
| Charles Schwab | 15,000 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 5,300 | 0 | 0 | 0 | For |
| John Hancock | 4,466 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 986 | 0 | 0 | 0 | For |
| BNY Mellon | 504 | 0 | 0 | 0 | For |
| American Century | 275 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 155 | 0 | 0 | 0 | For |
| Equitable | 150 | 0 | 0 | 0 | For |
| MassMutual | 46 | 0 | 0 | 0 | For |
| State Street | 23 | 0 | 0 | 0 | For |
| Nationwide | 19 | 0 | 0 | 0 | For |
| Guggenheim | 9 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 36,629,680 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.12% |
| 2 | Vanguard | 1.18% |
| 3 | FRANKLIN STRATEGIC SERIES | 0.70% |
| 4 | T. Rowe Price | 0.33% |
| 5 | BlackRock | 0.10% |
| 6 | Advisors' Inner Circle Fund III | 0.05% |
| 7 | Charles Schwab | 0.04% |
| 8 | ETFis Series Trust I | 0.01% |
| 9 | John Hancock | 0.01% |
| 10 | CARILLON SERIES TRUST | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 16.09% |
| 2 | VR Adviser, LLC | 5.80% |
| 3 | Avoro Capital Advisors LLC | 5.02% |
| 4 | COMMODORE CAPITAL LP | 5.01% |
| 5 | PERCEPTIVE ADVISORS LLC | 3.89% |
| 6 | Deep Track Capital, LP | 2.67% |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.46% |
| 8 | FRANKLIN ADVISERS INC | 2.03% |
| 9 | Cormorant Asset Management, LP | 1.88% |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.88% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 24.73% | 13F |
| BlackRock | 10.87% | 13F |
| RTW Investments, LP | 9.89% | 13G |
| TANG CAPITAL MANAGEMENT, LLC | 8.74% | 13G |
| Vanguard Group | 8.33% | 13F |
| Venrock Healthcare Capital Partners III, L.P. | 7.33% | 13G |
| Perceptive Advisors LLC | 7.03% | 13G |
| Wellington Management | 2.22% | 13F |
| Franklin Templeton | 2.03% | 13F |
| Citadel Advisors | 1.93% | 13F |
Percentages above are of 36,629,680 shares outstanding, as reported by SPYRE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SPYRE THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
SPYRE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “SPYRE THERAPEUTICS (SYRE) 2023-2024 Annual & Special Meetings”, https://proxyvotesnow.com/company/spyre-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.